X-Linked Hypophosphatemia Treatment Improves Phosphate Metabolism in PI/II Study: Kyowa Kirin

Kyowa Hakko Kirin announced on June 25 the results from a multiple-dose PI/II clinical study conducted in North America for its investigational anti-fibroblast growth factor 23 (FGF23) monoclonal antibody KRN23 in adult patients with X-linked hypophosphatemia (XLH). The data suggests...read more